Literature DB >> 12237781

Oestrogen receptor beta: how should we measure this?

V Speirs, P J Carder, M R J Lansdown.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12237781      PMCID: PMC2364250          DOI: 10.1038/sj.bjc.6600534

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


× No keyword cloud information.

Sir

Since a second oestrogen receptor (ER), ERβ was identified in the middle of the 1990s (Mosselman ), there has been much effort directed into trying to define its biological role in hormone sensitive tissue such as the mammary gland, particularly at the protein level. In a recent issue of British Journal of Cancer, Saunders reported immunohistochemical detection of ERβ in 51 breast tumours. In their study cohort, almost all samples were positive for ERβ (48 out of 51; 94%). In an earlier issue of British Journal of Cancer (Skliris ), we too reported immunohistochemical detection of ERβ in a similar sized cohort of 63 breast tumours, and showed much less positive nuclear ERβ immunoreactivity (48 out of 65; 74%). It is interesting to note that both studies used an identical scoring system, based on assessing both staining intensity (scored 0–3) and percentage positivity (scored 0–5), which generates a numerical score ranging from 0–8 (Allred ). In both instances, a score of >2 was considered positive. Why such divergent results in such similar sized cohorts? A Scottish–English patient bias seems unlikely (but has not been excluded!). However, it may be pertinent that each study used monoclonal antibodies directed against different parts of ERβ. More recent work from our group has shown a considerable variation in the efficacy of distinct ERβ antibodies to detect receptor protein under different applications (Skliris ) and Saunders also makes this point in her penultimate paragraph, when referring to other published immunohistochemical studies. It is also perhaps important to remind ourselves that the appropriate threshold for scoring a tumour as ‘positive’ for ERβ will remain unclear until immunohistochemical expression can be correlated with endocrine response in the clinical context. ERβ may well be an important player in the ER signalling cascade but until there is a recognised consensus on the best way to measure it in a clinically meaningful way, the waters will surely remain muddied.
  5 in total

1.  Evaluation of seven oestrogen receptor beta antibodies for immunohistochemistry, western blotting, and flow cytometry in human breast tissue.

Authors:  G P Skliris; A T Parkes; J L Limer; S E Burdall; P J Carder; V Speirs
Journal:  J Pathol       Date:  2002-06       Impact factor: 7.996

2.  ER beta: identification and characterization of a novel human estrogen receptor.

Authors:  S Mosselman; J Polman; R Dijkema
Journal:  FEBS Lett       Date:  1996-08-19       Impact factor: 4.124

Review 3.  Prognostic and predictive factors in breast cancer by immunohistochemical analysis.

Authors:  D C Allred; J M Harvey; M Berardo; G M Clark
Journal:  Mod Pathol       Date:  1998-02       Impact factor: 7.842

4.  Expression of oestrogen receptor beta (ERbeta1) protein in human breast cancer biopsies.

Authors:  P T K Saunders; M R Millar; K Williams; S Macpherson; C Bayne; C O'Sullivan; T J Anderson; N P Groome; W R Miller
Journal:  Br J Cancer       Date:  2002-01-21       Impact factor: 7.640

5.  Immunohistochemical detection of ERbeta in breast cancer: towards more detailed receptor profiling?

Authors:  G P Skliris; P J Carder; M R Lansdown; V Speirs
Journal:  Br J Cancer       Date:  2001-04-20       Impact factor: 7.640

  5 in total
  4 in total

1.  Synthesis and biological evaluation of two agents for imaging estrogen receptor β by positron emission tomography: challenges in PET imaging of a low abundance target.

Authors:  Jae Hak Lee; Olaf Peters; Lutz Lehmann; Carmen S Dence; Terry L Sharp; Kathryn E Carlson; Dong Zhou; M Jeyakumar; Michael J Welch; John A Katzenellenbogen
Journal:  Nucl Med Biol       Date:  2012-06-30       Impact factor: 2.408

2.  Design, synthesis, and evaluation of cyclofenil derivatives for potential SPECT imaging agents.

Authors:  Hua Zhu; Liliang Huang; Yuanqing Zhang; Xiaoping Xu; Yanhong Sun; Yu-Mei Shen
Journal:  J Biol Inorg Chem       Date:  2010-03-01       Impact factor: 3.358

3.  Fluorine-substituted cyclofenil derivatives as estrogen receptor ligands: synthesis and structure-affinity relationship study of potential positron emission tomography agents for imaging estrogen receptors in breast cancer.

Authors:  Jai Woong Seo; John S Comninos; Dae Yoon Chi; Dong Wook Kim; Kathryn E Carlson; John A Katzenellenbogen
Journal:  J Med Chem       Date:  2006-04-20       Impact factor: 7.446

Review 4.  Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance.

Authors:  Grazia Arpino; Lisa Wiechmann; C Kent Osborne; Rachel Schiff
Journal:  Endocr Rev       Date:  2008-01-23       Impact factor: 19.871

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.